Cited by 85Muscle Physiology and DisordersTelomeres, Telomerase, and SenescenceNeurogenetic and Muscular Disorders Research

Cellular senescence-mediated exacerbation of Duchenne muscular dystrophy

Open access
Sugihara, Hidetoshi, Teramoto, Naomi, Nakamura, Katsuyuki, Shiga, Takanori, Shirakawa, Taku, Matsuo, Masafumi, Ogasawara, Masashi, Nishino, Ichizo +3 more·2020·Scientific Reports

Abstract

Duchenne muscular dystrophy (DMD) is a progressive disease characterised by chronic muscle degeneration and inflammation. Our previously established DMD model rats (DMD rats) have a more severe disease phenotype than the broadly used mouse model. We aimed to investigate the role of senescence in DMD using DMD rats and patients. Senescence was induced in satellite cells and mesenchymal progenitor cells, owing to the increased expression of CDKN2A, p16- and p19-encoding gene. Genetic ablation of p16 in DMD rats dramatically restored body weight and muscle strength. Histological analysis showed a reduction of fibrotic and adipose tissues invading skeletal muscle, with increased muscle regeneration. Senolytic drug ABT263 prevented loss of body weight and muscle strength, and increased muscle regeneration in rats even at 8 months-the late stage of DMD. Moreover, senescence markers were highly expressed in the skeletal muscle of DMD patients. In situ hybridization of CDKN2A confirmed the expression of it in satellite cells and mesenchymal progenitor cells in patients with DMD. Collectively, these data provide new insights into the integral role of senescence in DMD progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-73315-6

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Senotherapy has proven to be effective in a rat model of Duchenne muscular dystrophy.

    “Senotherapy has also proven to be effective in a rat model of Duchenne muscular dystrophy, 29 a progressive disease characterised by chronic muscle degeneration and inflammation.”

    From The costs and benefits of senotherapeutics for human health (2022) · cites this paper as [29]

  • In children and young adults (3 to 33 years of age) affected by Duchene muscular dystrophy (DMD), p16 is evident in skeletal biopsy specimens while absent in age-matched peers without the disease.

    “In children and young adults (3 to 33 years of age) affected by Duchene muscular dystrophy (DMD), p16 is evident in skeletal biopsy specimens while absent in age-matched peers without the disease (Sugihara et al., 2020).”
  • In situ hybridization for CDKN2A mRNA suggest heightened expression in both satellite cells and FAPs in DMD.

    “Interesting, in situ hybridization for CDKN2A mRNA suggest heightened expression in both satellite cells and FAPs.”
  • Disease progression, marked by loss of body weight, skeletal muscle strength, and muscle fiber degeneration, was attenuated by ABT263 in the DMD rat model.

    “Moreover, disease progression, marked by loss of body weight, skeletal muscle strength, and muscle fiber degeneration, was attenuated by ABT263.”
  • In the DMD rat model, two cycles of 7 days of ABT263 separated by two weeks at a relatively late stage of disease (8 months) significantly reduced the expression of senescence markers in skeletal muscle, including p16, p19, p21, and a subset of SASP factors, compared to vehicle.

    “Notably, in the DMD rat model, two cycles of 7 days of ABT263 separated by two weeks at a relatively late stage of disease (8 months) significantly reduced the expression of senescence markers in skeletal muscle, including p16, p19, p21, and a subset of SASP factors, compared to vehicle (Sugihara et al., 2020).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

1 of the 80 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Sugihara, H., Teramoto, N., Nakamura, K., Shiga, T., Shirakawa, T., Matsuo, M., Ogasawara, M., Nishino, I., Matsuwaki, T., Nishihara, M., & Yamanouchi, K.
Affiliations
  • The University of Tokyo (JP)
  • Kobe Gakuin University (JP)
  • National Center of Neurology and Psychiatry (JP)
Corresponding author
Yamanouchi, Keitaro
Venue
Scientific Reports
Published
2020-10-12
Volume
10
Issue
1
Pages
16385-16385
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3092172736
Cited by
85
References
80
Citations by year
2026: 13 · 2025: 16 · 2024: 12 · 2023: 17 · 2022: 17 · 2021: 10
FWCI
3.57
Type
journal article
Language
en
Open access
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Intramural Research Grantor Neurological and Psychiatric Disorders of NCNP (29-4)
  • Japan Society for the Promotion of Science KAKENHI Grants (15K14883)
  • Japan Agency for Medical Research and Development (JP18nk0101342)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Genetics › Neurogenetic and Muscular Disorders Research
Keywords
Duchenne muscular dystrophy, cellular senescence, p16, CDKN2A, senolytic therapy, navitoclax, satellite cells, mesenchymal progenitor cells, muscle regeneration, muscle fibrosis, muscle strength, skeletal muscle
MeSH terms
Animals, Cells, Cultured, Disease Models, Animal, Humans, Mutation, Regeneration, Dystrophin, Cellular Senescence, Muscle, Skeletal, Cyclin-Dependent Kinase Inhibitor p16, Muscular Dystrophy, Duchenne, Satellite Cells, Skeletal Muscle, Mice, Rats, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review